• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Catalent soars on Q3 earnings, sales beat

May 9, 2017 By Sarah Faulkner

CatalentShares in Catalent (NYSE:CTLT) jumped more than 20% last week after the company beat expectations on Wall Street with its fiscal 3rd quarter results.

The Somersert, N.J.-based company posted profits of $26 million, or 21¢ per share, on sales of $532.6 million for the 3 months ended March 31, for bottom-line growth of 143% on sales growth of 22% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were 38¢, ahead of consensus on The Street, where analysts were looking for sales of $470.9 million.

“We’re pleased with our performance during the 3rd quarter, where we recorded double-digit organic revenue growth on a constant currency across all 3 of our reporting segments, and closed our 2nd strategic acquisition of the fiscal year,” president & CEO John Chiminski said in prepared remarks. “The integrations of both acquisitions closed during the fiscal year, Pharmatek and Accucaps, are progressing according to our expectations and are already creating value for the company and our shareholders.”

CTLT shares were trading at $31.47 apiece today in mid-afternoon activity, up 0.3%.

Catalent said in February that it closed its acquisition of Canada-based Accucaps and its pharmaceutical soft-gel manufacturing capabilities. The company did not disclose the deal’s financial details.

In November last year, Catalent said that it planned to fund the Accucaps buy with a $400 million debt offering.

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Catalent

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS